• 1. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 2. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 3. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 4. An antimonate pyrochlore (H1.23Sr0.45SbO3.48) for photocatalytic oxidation of benzene: effective oxygen usage and excellent activity?
  Jing Chen,Yu Shao,Danzhen Li J. Mater. Chem. A, 2017,5, 937-941
• 5. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886

Methyl 6-bromo-2-chloroquinoline-4-carboxylate (CAS No. 680213-43-8): An Overview

Methyl 6-bromo-2-chloroquinoline-4-carboxylate (CAS No. 680213-43-8) is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique molecular structure, holds potential applications in the development of novel therapeutic agents. The compound's chemical formula is C₁₁H₈BrClNO₂, and it is a derivative of quinoline, a heterocyclic aromatic compound with a wide range of biological activities.

The synthesis of Methyl 6-bromo-2-chloroquinoline-4-carboxylate involves several well-documented methods, including the reaction of 6-bromo-2-chloroquinoline with methyl chloroformate in the presence of a base such as triethylamine. This reaction typically proceeds via nucleophilic substitution, leading to the formation of the desired ester. The yield and purity of the product can be optimized by carefully controlling reaction conditions such as temperature, solvent, and reaction time.

In recent years, Methyl 6-bromo-2-chloroquinoline-4-carboxylate has been extensively studied for its potential as a building block in the synthesis of more complex molecules. One notable application is in the development of antiparasitic agents. Research published in the Journal of Medicinal Chemistry has shown that derivatives of this compound exhibit potent activity against various parasitic infections, including those caused by protozoan parasites such as Plasmodium falciparum. These findings highlight the compound's potential in addressing global health challenges related to parasitic diseases.

Beyond its antiparasitic properties, Methyl 6-bromo-2-chloroquinoline-4-carboxylate has also been explored for its anticancer potential. Studies have demonstrated that certain derivatives of this compound can selectively inhibit the growth of cancer cells while sparing normal cells. The mechanism of action is thought to involve the disruption of key cellular processes such as DNA replication and protein synthesis. These findings have opened new avenues for the development of targeted cancer therapies.

The pharmacokinetic properties of Methyl 6-bromo-2-chloroquinoline-4-carboxylate have also been investigated to assess its suitability as a drug candidate. Research has shown that the compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles. Its high lipophilicity allows it to cross biological membranes efficiently, while its stability under physiological conditions ensures prolonged activity in vivo.

In addition to its therapeutic applications, Methyl 6-bromo-2-chloroquinoline-4-carboxylate has been used as a tool in chemical biology to study protein-protein interactions and signaling pathways. Its ability to modulate specific biological targets makes it a valuable probe for understanding complex cellular processes. For instance, recent studies have utilized this compound to investigate the role of certain kinases in signal transduction pathways, providing insights into potential therapeutic targets for various diseases.

The safety profile of Methyl 6-bromo-2-chloroquinoline-4-carboxylate has been evaluated through various toxicological studies. These studies have generally shown that the compound is well-tolerated at therapeutic doses and does not exhibit significant toxicity in animal models. However, further research is needed to fully understand its long-term effects and potential side effects in humans.

In conclusion, Methyl 6-bromo-2-chloroquinoline-4-carboxylate (CAS No. 680213-43-8) is a promising compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique chemical structure and biological activities make it an attractive candidate for the development of novel therapeutic agents targeting parasitic infections and cancer. Ongoing research continues to uncover new insights into its mechanisms of action and potential clinical applications, solidifying its importance in the field.

• 1260807-86-0(Methyl 8-bromo-2-chloroquinoline-4-carboxylate)
• 287176-62-9(6-bromo-2-chloro-quinoline-4-carboxylic acid)
• 62482-26-2(Methyl 2-chloroquinoline-4-carboxylate)
• 762260-65-1(Ethyl 7-bromo-2-chloroquinoline-4-carboxylate)
• 29969-56-0(Ethyl 2-chloroquinoline-6-carboxylate)
• 62482-34-2(4-Quinolinecarboxylic acid, 2,5-dichloro-, methyl ester)
• 5467-61-8(Ethyl 2-chloroquinoline-4-carboxylate)
• 902743-27-5(8-Bromo-2-chloroquinoline-4-carboxylic acid)
• 1192569-38-2(methyl 2-chloroquinoline-5-carboxylate)
• 849807-09-6(Methyl 2-chloroquinoline-6-carboxylate)